A phase-III, multicenter, randomized, double-blind, placebo-controlled trial demonstrated that tolvaptan reduced body weight significantly in patients with hepatic edema and low serum level of albumin (< 2.5 g/dl), suggesting that tolvaptan could improve hepatic edema independent of the serum level of albumin [14]. Here, ALB is linked to edema.